Abiopharma

Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dermata Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

4DMT Announces New Employment Inducement Grants

Nuvalent Announces Timing of Topline Pivotal Data for TKI Pre-treated Patients with Advanced ALK-positive NSCLC from ALKOVE-1 Clinical Trial of Neladalkib

Femasys Announces Third Quarter Financial Results for 2025

Delcath Systems, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity

Retractable Technologies, Inc. Results for the Periods Ended September 30, 2025

UTHR: Notification